Reuters · Apr 2026
Humana's CenterWell Pharmacy partnered with Cost Plus Drugs to use its SwiftyRx platform, extend mail-order options, and co-develop an employer prescription solution.
Making low cost versions of high cost generic drugs.
Public company, workplace, funding, and market signals
Public-benefit, vertically integrated pharmaceutical company that sells transparent low-cost prescriptions through a direct-to-consumer online pharmacy, B2B employer/MCO offerings, wholesale distribution, and manufacturing capacity aimed at drug shortages.
Primary product
Transparent low-cost online pharmacy and prescription drug platform
Founded
2016
Headquarters
Dallas, Texas, United States
Team size
50-60
Industry
Pharmaceutical Manufacturing
Sub-industry
Online pharmacy / pharmaceutical manufacturing
Offices
0 jobs at Mark Cuban Cost Plus Drug Company, PBC
Check back later for new openings
Business model
Stage
Seed / generating revenue
Total raised
$1.4M
Latest round
Seed · Jan 2019
Latest amount
$1.3M
Leadership
Co-founder
CEO / Co-founder
Chief Financial Officer
Chief Commercial Officer / Vice President - Commercial Operations
Vice President of Trade Relations & Pharmaceutical Contracting
Chief of Pharmacy Relations, Network & Professional Affairs
Chief Supply Chain Officer
Investors
Mission-driven, public-benefit culture centered on transparency, affordability, patient access, and cross-functional execution across manufacturing, pharmacy, and employer channels.
Pricing
Cost-plus pricing: manufacturer acquisition cost plus a fixed 15% markup, plus pharmacy labor/dispensing and shipping charges; B2B offerings emphasize pass-through pricing with no rebates.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1B-$2B
Estimated monthly visits
1.2M
Traffic estimate as of Jun 2026
Reuters · Apr 2026
Humana's CenterWell Pharmacy partnered with Cost Plus Drugs to use its SwiftyRx platform, extend mail-order options, and co-develop an employer prescription solution.
Reuters · Apr 2026
Bristol Myers Squibb and Pfizer agreed to sell Eliquis through CostPlusDrugs.com, expanding direct-to-patient access and adding a major brand drug to the platform.
Reuters · Dec 2025
Cuban urged FDA fee relief to accelerate U.S. generic manufacturing, saying Cost Plus Drugs would expand domestic production if the regulatory burden were reduced.
Reuters · Jun 2025
Cost Plus Drugs partnered with 9amHealth to offer employer-focused obesity and chronic-condition treatment options, including access to cheaper medications.
Reuters · Jul 2024
Cost Plus Drugs worked with the FDA to import and distribute penicillin temporarily to mitigate a U.S. shortage.